Rates of re-excision and conversion to mastectomy after breast-conserving surgery with or without oncoplastic surgery: a nationwide population-based study

E. Heeg1,2, M. B. Jensen4, L. R. Hölmič6, A. Bodilsen7, R. A. E. M. Tollenaar2, A. V. Lænholm10, B. V. Offerse8, B. Ejlersen4,5, M. A. M. Mureau3 and P. M. Christiansen9

1Dutch Institute for Clinical Auditing, and 2Department of Surgery, Leiden University Medical Centre, Leiden, and 3Department of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, the Netherlands, 4Danish Breast Cancer Cooperative Group, and 5Department of Oncology, Rigshospitalet, Copenhagen, 6Department of Plastic Surgery, Herlev Gentofte Hospital, Herlev, Departments of 7Surgery, 8Oncology and 9Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, and 10Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark

Correspondence to: Dr E. Heeg, Danish Breast Cancer Cooperative Group, Blegdamsvej 9, Copenhagen DK2100, Denmark (e-mail: e.heeg@lumc.nl)

Background: There is no consensus regarding the impact of oncoplastic surgery (OPS) on rates of re-excision and conversion to mastectomy following breast-conserving surgery (BCS). Here these two outcomes after BCS and OPS were compared in a nationwide population-based setting.

Methods: In Denmark, all OPS is registered and categorized into volume displacement, volume reduction or volume replacement. Patients who underwent BCS or OPS between 2012 and 2018 were selected from the Danish Breast Cancer Group database. Multivariable analyses were performed to adjust for confounders, and propensity score matching to limit potential confounding by indication bias.

Results: A total of 13 185 patients (72.5 per cent) underwent BCS and 5003 (27.5 per cent) OPS. Volume displacement was used in 4171 patients (83.4 per cent), volume reduction in 679 (13.6 per cent) and volume replacement in 153 (3.1 per cent). Re-excision rates were 15.6 and 14.1 per cent after BCS and OPS respectively. After adjusting for confounders, patients were less likely to have a re-excision following OPS than BCS (odds ratio (OR) 0.80, 95 per cent c.i. 0.72 to 0.88), specifically after volume displacement and reduction. The rate of conversion to mastectomy was similar after OPS and BCS (3.2 versus 3.7 per cent; \( P = 0.105 \)), but with a lower risk in adjusted analysis (OR 0.69, 0.58 to 0.84), specifically after volume displacement and reduction procedures. Findings were similar after propensity score matching.

Conclusion: A modest decrease in re-excision rate and less frequent conversion to mastectomy were observed after OPS compared with BCS.

Paper accepted 31 May 2020
Published online 6 August 2020 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11838

Introduction

Randomized trials1–5 conducted in the 1980s established breast-conserving surgery (BCS) followed by radiotherapy as the preferred treatment for early-stage breast cancer. Improved breast cancer survival rates6,7 have led to an increased focus on cosmetic outcomes after treatment8. Consequently, a challenging balance has emerged between achieving complete resection of the tumour with appropriate tumour-free margins and a favourable cosmetic result. Not every patient is eligible for BCS owing to anatomical and tumour characteristics9.

Oncoplastic surgery (OPS) improves cosmetic outcomes and is nowadays used in up to 34 per cent of patients with breast cancer undergoing BCS10–14. Previous studies15,16 have demonstrated that by using OPS breast conservation becomes an alternative to mastectomy in patients with large and multifocal tumours. Compared with BCS, OPS is associated with larger resections17,18, and good long-term survival outcomes11,13,18,19 and quality of life20–22. Achieving larger tumour resections with OPS may also reduce the number of re-excisions owing to insufficient margins. High-quality evidence regarding the impact of OPS on re-excisions is, however, sparse18,19.

Between 2000 and 2009, re-excision after BCS occurred in about 17 per cent of patients with breast cancer in Denmark23, which is within the reported range of 5–35

© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS 2020; 107: 1762–1772
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Impact of oncoplastic surgery on rates of re-excision and conversion to mastectomy

per cent22,24–26. Re-excision requiring mastectomy is commonly defined as conversion to mastectomy. Re-excision and conversion to mastectomy are associated with more morbidity, complications, poorer aesthetic outcome, greater patient distress and increased healthcare costs27,28. Furthermore, for patients in whom free margins were not achieved during primary BCS, an increased risk of ipsilateral breast tumour recurrence has been reported23.

In Denmark, OPS techniques have been registered prospectively by the Danish Breast Cancer Group (DBCG) for all patients undergoing BCS since July 2010. The primary goal of the present study was to compare re-excision rates after BCS versus OPS in patients with early-stage breast cancer, in a population-based national setting. A further aim was to investigate whether OPS results in a lower conversion to mastectomy rate (CMR) than BCS. As several studies11–13,29 have shown that patients may not have the same likelihood of receiving OPS based on their baseline characteristics, additional propensity score matching was used to limit the potential confounding by indication bias.

Methods

Since 1978, the DBCG has collected clinicopathological and treatment characteristics and follow-up data prospectively from all patients diagnosed with a primary invasive breast cancer30. OPS is categorized into three types: volume displacement, defined as local rearrangement of tissue near the lumpectomy cavity in order to close the defect; volume reduction, defined as the use of a breast reduction technique to remove tumour and improve breast shape at the same time; and volume replacement, defined as tissue transfer from outside the breast into the breast (such as local perforator flaps). A more detailed description of data collection by the DBCG has been published30,31. The study was approved by the Scientific Committee of Surgery within the DBCG and the Danish Clinical Registries.

Study population

All women with invasive breast cancer without distant metastasis, who underwent primary BCS between January 2012 and December 2018, identified from the DBCG database were included. Patients who received neoadjuvant therapy or surgical biopsy as the only surgical procedure were excluded. Patients were categorized into four groups: BCS (without OPS), OPS with volume displacement, OPS with volume reduction, and OPS with volume replacement.

Outcomes

The primary outcome was re-excision, defined as a second BCS procedure or mastectomy following the primary BCS within 2 months of the initial operation. This interval was chosen to limit potential re-excisions owing to breast cancer recurrence. Information about re-excision, including type, was retrieved from Danish National Patient Registry32. Re-excision rates among patients aged over 50 years might be influenced by use of boost radiation for treatment of insufficient margins, so secondary interventions (re-excision or boost radiation) were compared in patients aged 50 years or older undergoing BCS or OPS. The secondary outcome, CMR, was defined as the rate of mastectomy following the primary BCS within 2 months of the initial operation.

Confounders

Co-morbidity was classified according to the Charlson Co-morbidity Index (CCI)33. Histological subtypes, such as papillary, medullary and mucinous subtypes, were categorized as ‘other’. In Denmark, grading is applied to invasive ductal and lobular carcinomas, but not to subtypes classified as ‘other’, according to the modified version of the Bloom Richardson scoring system of Elston and Ellis34. Breast cancer was classified as oestrogen receptor-positive when at least 10 per cent of cells stained positive in immunohistochemical analyses. Expression of human epidermal growth factor receptor 2 (HER2) was determined according to standard recommendations35. Tumour size and lymph node status were categorized according to the seventh edition of the AJCC cancer staging classification36. Any missing characteristics were classified as unknown.

Guidelines

In accordance with Danish guidelines30,31, re-excision was advised if invasive carcinoma was identified at the inked margins or ductal carcinoma in situ (DCIS) within 2 mm from the margin. Danish guidelines also recommend boost radiation in all patients younger than 50 years after BCS with or without OPS; and in those with a microscopic free margin of less than 2 mm for invasive breast cancer or DCIS, irrespective of age37,38.

Statistical analysis

Patient and tumour characteristics were compared between BCS and OPS groups using $\chi^2$ test for categorical variables, and Mann–Whitney $U$ test or Kruskal–Wallis test for continuous variables. Unknown characteristics were included
in the descriptive statistics. Two-sided \( P < 0.050 \) was considered statistically significant. To adjust for confounders, a multivariable logistic regression model was used to estimate whether patients who underwent OPS were more likely to have a re-excision than those who had BCS. Results were expressed as odds ratios (ORs) with 95 per cent confidence intervals, and the Wald test was used for analysis of statistical significance. The latter analyses were repeated for the secondary outcome CMR. Patients with unknown variables were included as a separate category in all analyses.

To evaluate whether associations were subject to confounding by indication, meaning that not all patients were equally likely to have received OPS, analyses were repeated in propensity score-matched cohorts. Patients who underwent BCS were matched with those who had OPS as a whole and by each type of OPS. Patients were matched on the likelihood of undergoing OPS using the following co-variables: year of operation, age, CCI score, histological finding, differentiation grade, oestrogen receptor positivity, HER2 status, T and N status\(^{39,40}\). Patients who underwent BCS were matched 1 : 1 with those who had OPS (mean(s.d.) 62\( \cdot \)9 (11\( \cdot \)5) years; \( P < 0.001 \)) (Table 1). Patients who underwent OPS had a lower co-morbidity score than those who had BCS (\( P < 0.001 \)), but poorer prognostic tumour factors, including higher differentiation grade (\( P < 0.001 \)), larger tumour size (\( P < 0.001 \)) and more lymph node involvement (\( P < 0.001 \)). The use of OPS decreased significantly from 30\( \cdot \)3 per cent in 2012 to 26\( \cdot \)4 per cent in 2018 (\( P < 0.001 \)).

OPS was performed with volume displacement in 4171 patients (83\( \cdot \)4 per cent), volume reduction in 679 (13\( \cdot \)6 per cent) and volume replacement in 153 (3\( \cdot \)1 per cent). Patients who underwent OPS with volume reduction or replacement had lower co-morbidity scores (\( P = 0.020 \)), larger tumours (\( P < 0.001 \)) and more lymph node involvement (\( P < 0.001 \)) than those who had volume displacement (Table 2). Baseline characteristics of patients who underwent the three types of OPS are provided in Table 2.

In total, 2763 patients (15\( \cdot \)2 per cent) underwent re-excision, in whom the final surgical treatment was BCS in 2108 patients (76\( \cdot \)3 per cent) and mastectomy in 655 (23\( \cdot \)7 per cent). The re-excision rate was 15\( \cdot \)6 per cent for patients who underwent BCS and 14\( \cdot \)1 per cent among those who had OPS (\( P = 0.012 \)). Re-excision rates varied according to OPS technique: 14\( \cdot \)5 per cent for volume displacement, 10\( \cdot \)3 per cent for volume reduction and 20\( \cdot \)9 per cent for volume replacement (Table 3). The unadjusted re-excision rate did not change significantly over time (\( P = 0.438 \)).

Multivariable analysis showed that patients who underwent OPS were less likely to undergo re-excision than those who had BCS (adjusted OR 0\( \cdot \)80, 95 per cent c.i. 0\( \cdot \)72 to 0\( \cdot \)88). Subsequent analyses showed that patients who underwent OPS with volume displacement (OR 0\( \cdot \)83, 0\( \cdot \)75 to 0\( \cdot \)92) or volume reduction (OR 0\( \cdot \)50, 0\( \cdot \)39 to 0\( \cdot \)65) were less likely to undergo re-excision than those who had BCS (Table 3). Patients who underwent OPS with volume replacement had the same likelihood of re-excision as the BCS group (OR 1\( \cdot \)16, 0\( \cdot \)78 to 1\( \cdot \)73).

Other characteristics associated with re-excision were lobular or other histological subtype, higher differentiation grade, unknown oestrogen receptor status, positive HER2 status, larger tumour size and lymph node involvement (Table 3). Re-excisions were less likely with increasing age. Year of surgery and co-morbidity were not associated with re-excision.

A shift from an imbalance in characteristics before propensity score matching to a balance after matching was observed when the BCS group was matched with the OPS group as a whole, and by type of OPS (Tables S1 – S4, supporting information). In the matched cohort with OPS as a whole, re-excision was less likely after OPS than BCS (OR 0\( \cdot \)79, 0\( \cdot \)71 to 0\( \cdot \)88), similar to the results of multivariable analysis of the unmatched study population. Matched patients who underwent OPS with volume displacement (OR 0\( \cdot \)80, 0\( \cdot \)71 to 0\( \cdot \)90) or volume reduction (0\( \cdot \)46, 0\( \cdot \)34 to 0\( \cdot \)63) were less likely to undergo re-excision than the BCS group, whereas patients who underwent OPS with volume replacement had the same likelihood of re-excision as patients who had BCS (OR 1\( \cdot \)13, 0\( \cdot \)65 to 1\( \cdot \)98).

Further analyses showed similar use of secondary interventions in patients older than 50 years undergoing BCS or OPS (16\( \cdot \)4 versus 15\( \cdot \)9 per cent; \( P = 0.430 \)). However, among patients who had secondary interventions, boost radiation was used less often in patients who underwent BCS compared with those who had OPS (14\( \cdot \)7 versus 21\( \cdot \)2 per cent; \( P < 0.001 \)).
Table 1 Baseline characteristics of patients who underwent breast-conserving surgery or oncoplastic surgery

|                          | All patients (n = 18 188) | BCS (n = 13 185) | OPS (n = 5003) | P† |
|--------------------------|---------------------------|-----------------|---------------|----|
| **Year of operation**    |                           |                 |               |    |
| 2012                     | 2667 (14-7)               | 1858 (14-1)     | 809 (16-2)    |    |
| 2013                     | 2733 (15-0)               | 2052 (15-6)     | 681 (13-8)    |    |
| 2014                     | 2751 (15-1)               | 1933 (14-7)     | 818 (16-4)    |    |
| 2015                     | 2626 (14-4)               | 1909 (14-5)     | 717 (14-3)    |    |
| 2016                     | 2533 (13-9)               | 1852 (14-0)     | 681 (13-6)    |    |
| 2017                     | 2476 (13-6)               | 1813 (13-8)     | 663 (13-3)    |    |
| 2018                     | 2402 (13-2)               | 1768 (13-4)     | 634 (12-7)    |    |
| **Age (years)**          | 61.5(11-5)                | 62.1(11-5)      | 59.9(11-5)    | <0.001‡ |
| **Charlson Co-morbidity Index score** | <0.001                     |                 |               |    |
| 0                        | 13 987 (76-9)             | 9942 (75-4)     | 4045 (80-9)   |    |
| 1                        | 2500 (13-7)               | 1910 (14-5)     | 590 (11-8)    |    |
| 2                        | 1118 (6-1)                | 868 (6-6)       | 250 (6-0)     |    |
| ≥3                       | 583 (3-2)                 | 465 (3-5)       | 118 (2-4)     |    |
| **Histological finding** |                           |                 |               |    |
| Ductal                   | 14 777 (81-2)             | 10 669 (80-9)   | 4108 (82-1)   |    |
| Lobular                  | 1888 (10-4)               | 1339 (10-2)     | 549 (11-0)    |    |
| Other                    | 1505 (8-3)                | 1161 (8-8)      | 344 (6-9)     |    |
| Unknown                  | 18 (0-1)                  | 16 (0-1)        | 2 (0-0)       |    |
| **Differentiation grade**|                           |                 |               |    |
| I                        | 4809 (26-4)               | 3683 (27-9)     | 1126 (22-5)   |    |
| II                       | 7958 (43-8)               | 5700 (43-2)     | 2258 (45-1)   |    |
| III                      | 3747 (20-6)               | 2496 (18-9)     | 1251 (25-0)   |    |
| Not determined           | 1505 (8-3)                | 1161 (8-8)      | 344 (6-9)     |    |
| Unknown                  | 169 (0-9)                 | 145 (1-1)       | 24 (0-5)      |    |
| **Oestrogen receptor (%)**|                           |                 |               |    |
| <10                      | 2272 (12-5)               | 1562 (11-8)     | 710 (14-2)    |    |
| ≥10                      | 15 867 (87-2)             | 11 583 (87-8)   | 4284 (85-6)   |    |
| Unknown                  | 49 (0-3)                  | 40 (0-3)        | 9 (0-2)       |    |
| **HER2 status**          |                           |                 |               |    |
| Negative                 | 16 086 (88-4)             | 11 751 (89-1)   | 4335 (86-6)   |    |
| Positive                 | 1916 (10-5)               | 1281 (9-7)      | 635 (12-7)    |    |
| Unknown                  | 186 (1-0)                 | 153 (1-2)       | 33 (0-7)      |    |
| **T category**           |                           |                 |               |    |
| T1                       | 14 302 (78-6)             | 10 854 (82-3)   | 3448 (68-9)   |    |
| T2                       | 3790 (20-8)               | 2264 (17-2)     | 1526 (30-5)   |    |
| T3                       | 85 (0-5)                  | 57 (0-4)        | 28 (0-6)      |    |
| Unknown                  | 11 (0-1)                  | 10 (0-1)        | 1 (0-0)       |    |
| **N category**           |                           |                 |               |    |
| N0                       | 12 649 (69-5)             | 9397 (71-3)     | 3252 (65-0)   |    |
| N1                       | 4220 (23-2)               | 2818 (21-4)     | 1402 (28-0)   |    |
| N2                       | 673 (3-7)                 | 436 (3-3)       | 237 (4-7)     |    |
| N3                       | 313 (1-7)                 | 226 (1-7)       | 87 (1-7)      |    |
| Unknown                  | 333 (1-8)                 | 308 (2-3)       | 25 (0-5)      |    |

Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). BCS, breast-conserving surgery; OPS, oncoplastic surgery; HER2, human epidermal growth factor receptor 2. †χ² test, except ‡Mann–Whitney U test.
|                          | Volume displacement (n = 4171) | Volume reduction (n = 679) | Volume replacement (n = 153) | P† |
|--------------------------|-------------------------------|---------------------------|-----------------------------|----|
| **Year of operation**    |                               |                           |                             |    |
| 2012                     | 658 (15-8)                    | 113 (16-6)                | 38 (24-8)                   | <0.001 |
| 2013                     | 536 (12-9)                    | 119 (17-5)                | 26 (17-0)                   |    |
| 2014                     | 680 (16-3)                    | 111 (16-3)                | 27 (17-6)                   |    |
| 2015                     | 609 (14-6)                    | 88 (13-0)                 | 20 (13-1)                   |    |
| 2016                     | 561 (13-5)                    | 97 (14-3)                 | 23 (15-0)                   |    |
| 2017                     | 583 (14-0)                    | 72 (10-6)                 | 8 (5-2)                     |    |
| 2018                     | 544 (13-0)                    | 79 (11-6)                 | 11 (7-2)                    |    |
| **Age (years)***         | 601 (11-5)                    | 589 (11-2)                | 574 (10-3)                  | <0.001‡ |
| **Charlson Co-morbidity Index score** |                               |                           |                             | 0.020 |
| 0                        | 3355 (80-4)                   | 557 (82-0)                | 133 (86-0)                  |    |
| 1                        | 515 (12-3)                    | 63 (9-3)                  | 12 (7-8)                    |    |
| 2                        | 198 (4-7)                     | 44 (6-5)                  | 8 (5-2)                     |    |
| ≥ 3                      | 103 (2-5)                     | 15 (2-2)                  | 0 (0)                       |    |
| **Histological finding** |                               |                           |                             | 0.909 |
| Ductal                   | 3418 (81-9)                   | 563 (82-9)                | 127 (83-0)                  |    |
| Lobular                  | 456 (10-9)                    | 75 (11-0)                 | 18 (11-8)                   |    |
| Other                    | 295 (7-1)                     | 41 (6-0)                  | 8 (5-2)                     |    |
| Unknown                  | 2 (0-0)                       | 0 (0)                     | 0 (0)                       |    |
| **Differentiation grade**|                               |                           |                             | 0.071 |
| I                        | 963 (23-1)                    | 131 (19-3)                | 32 (20-9)                   |    |
| II                       | 1884 (45-2)                   | 299 (44-0)                | 75 (49-0)                   |    |
| III                      | 1010 (24-2)                   | 204 (30-0)                | 37 (24-2)                   |    |
| Not determined           | 295 (7-1)                     | 41 (6-0)                  | 8 (5-2)                     |    |
| Unknown                  | 19 (0-5)                      | 4 (0-6)                   | 1 (0-7)                     |    |
| **Oestrogen receptor (%)**|                               |                           |                             | 0.752 |
| <10                      | 592 (14-2)                    | 95 (14-0)                 | 23 (15-0)                   |    |
| ≥ 10                     | 3570 (85-6)                   | 584 (86-0)                | 130 (85-0)                  |    |
| Unknown                  | 9 (0-2)                       | 0 (0)                     | 0 (0)                       |    |
| **HER2 status**          |                               |                           |                             | 0.721 |
| Negative                 | 3620 (86-8)                   | 581 (85-6)                | 134 (87-6)                  |    |
| Positive                 | 522 (12-5)                    | 94 (13-8)                 | 19 (12-4)                   |    |
| Unknown                  | 29 (0-7)                      | 4 (0-6)                   | 0 (0)                       |    |
| **T category**           |                               |                           |                             | <0.001 |
| T1                       | 3000 (71-9)                   | 370 (54-5)                | 78 (51-0)                   |    |
| T2                       | 1152 (27-6)                   | 300 (44-2)                | 74 (48-4)                   |    |
| T3                       | 18 (0-4)                      | 9 (1-3)                   | 1 (0-7)                     |    |
| Unknown                  | 1 (0-0)                       | 0 (0)                     | 0 (0)                       |    |
| **N category**           |                               |                           |                             | 0.006 |
| N0                       | 2749 (65-9)                   | 417 (61-4)                | 86 (56-2)                   |    |
| N1                       | 1134 (27-2)                   | 215 (31-7)                | 53 (34-6)                   |    |
| N2                       | 190 (4-6)                     | 39 (5-7)                  | 8 (5-2)                     |    |
| N3                       | 74 (1-8)                      | 7 (1-0)                   | 6 (3-9)                     |    |
| Unknown                  | 24 (0-6)                      | 1 (0-1)                   | 0 (0)                       |    |

Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). HER2, human epidermal growth factor receptor 2. †χ² test, except ‡Kruskal–Wallis test.
Table 3 Univariable and multivariable logistic regression analyses of characteristics predictive of re-excision

| Type of surgery               | Re-excision | Odds ratio† | P‡ | Univariable analysis (n = 18 188) | Multivariable analysis (n = 18 188) |
|-------------------------------|-------------|-------------|----|----------------------------------|------------------------------------|
| BCS                           | 11 128 (84-4) | 2057 (15-6) | 1.00 (reference) | 1.00 (reference) |
| Volume displacement           | 3567 (85-5)  | 604 (14-5)  | 0.92 (0.83, 1.01) | 0.83 (0.75, 0.92) |
| Volume reduction              | 609 (89-7)   | 70 (10-3)   | 0.62 (0.48, 0.80) | 0.50 (0.39, 0.65) |
| Volume replacement            | 121 (79-1)   | 32 (20-9)   | 1.43 (0.97, 2.12) | 1.16 (0.78, 1.73) |

| Year of operation             |             |             |    |                                  |                                    |
|-------------------------------|-------------|-------------|----|----------------------------------|------------------------------------|
| 2012                          | 2295 (86-1) | 372 (13-9)  | 1.00 (reference) | 1.00 (reference) |
| 2013                          | 2332 (85-3) | 401 (14-7)  | 1.06 (0.91, 1.24) | 1.07 (0.92, 1.25) |
| 2014                          | 2330 (84-7) | 421 (15-3)  | 1.12 (0.96, 1.30) | 1.12 (0.96, 1.31) |
| 2015                          | 2208 (84-1) | 418 (15-9)  | 1.17 (1.00, 1.36) | 1.19 (1.02, 1.39) |
| 2016                          | 2144 (84-6) | 389 (15-4)  | 1.12 (0.96, 1.31) | 1.13 (0.97, 1.33) |
| 2017                          | 2083 (84-1) | 393 (15-9)  | 1.16 (1.00, 1.36) | 1.21 (1.04, 1.42) |
| 2018                          | 2033 (84-6) | 369 (15-4)  | 1.12 (0.96, 1.31) | 1.19 (1.01, 1.39) |

| Age (years)*                 |             |             |    |                                  |                                    |
|-------------------------------|-------------|-------------|----|----------------------------------|                                    |
| 61-8(11-6)                   | 59-9(11-2)  | 0.99 (0.98, 0.99) | 0.99 (0.98, 0.99) |

| Charlson Co-morbidity index score |             |             |    |                                  |                                    |
|----------------------------------|-------------|-------------|----|----------------------------------|                                    |
| 0                                | 11 1790 (84-3) | 2197 (15-7) | 1.00 (reference) | 1.00 (reference) |
| 1                                | 2148 (85-9)   | 352 (14-1)  | 0.88 (0.78, 0.99) | 0.94 (0.83, 1.07) |
| 2                                | 962 (86-0)    | 156 (14-0)  | 0.87 (0.73, 1.04) | 0.96 (0.81, 1.15) |
| ≥3                               | 525 (90-1)    | 58 (9-9)    | 0.59 (0.45, 0.78) | 0.69 (0.52, 0.91) |

| Histological finding           |             |             |    |                                  |                                    |
|--------------------------------|-------------|-------------|----|----------------------------------|                                    |
| Ductal                         | 12 614 (84-5) | 2163 (14-6) | 1.00 (reference) | 1.00 (reference) |
| Lobular                        | 1527 (80-9)  | 361 (19-1)  | 1.38 (1.22, 1.56) | 1.40 (1.23, 1.59) |
| Other                          | 1269 (84-3)  | 236 (15-7)  | 1.09 (0.94, 1.26) | 1.45 (1.22, 1.71) |
| Unknown                        | 15 (83-3)    | 3 (16-7)    | 1.17 (0.34, 4.03) | 0.18 (0.04, 0.78) |

| Differentiation grade          |             |             |    |                                  |                                    |
|--------------------------------|-------------|-------------|----|----------------------------------|                                    |
| I                              | 4246 (88-3) | 563 (11-7)  | 1.00 (reference) | 1.00 (reference) |
| II                             | 6658 (83-7) | 1300 (16-3) | 1.35 (1.23, 1.48) | 1.32 (1.19, 1.47) |
| III                            | 3141 (83-8) | 606 (16-2)  | 1.33 (1.19, 1.49) | 1.18 (1.03, 1.36) |
| Not determined                 | 1269 (84-3) | 236 (15-7)  | – | – |                                    |
| Unknown                        | 111 (65-7)  | 58 (34-3)   | 3.61 (2.60, 5.00) | 3.69 (2.57, 5.30) |

| Oestrogen receptor (%)         |             |             |    |                                  |                                    |
|--------------------------------|-------------|-------------|----|----------------------------------|                                    |
| < 10                           | 1902 (83-7) | 370 (16-3)  | 1.10 (0.98, 1.24) | 0.97 (0.85, 1.12) |
| ≥ 10                           | 13 490 (85-0) | 2377 (15-0) | 1.00 (reference) | 1.00 (reference) |
| Unknown                        | 33 (67-3)   | 16 (32-7)   | 2.75 (1.51, 5.01) | 3.69 (1.66, 8.21) |

| HER2 status                    |             |             |    |                                  |                                    |
|--------------------------------|-------------|-------------|----|----------------------------------|                                    |
| Negative                       | 13 775 (85-6) | 2311 (14-4) | 1.00 (reference) | 1.00 (reference) |
| Positive                       | 1496 (78-1) | 420 (21-9)  | 1.67 (1.49, 1.88) | 1.60 (1.42, 1.81) |
| Unknown                        | 154 (82-8)  | 32 (17-2)   | 1.24 (0.84, 1.82) | 0.85 (0.52, 1.38) |

| T category                     |             |             |    |                                  |                                    |
|--------------------------------|-------------|-------------|----|----------------------------------|                                    |
| T1                             | 12 284 (85-9) | 2018 (14-1) | 1.00 (reference) | 1.00 (reference) |
| T2                             | 3097 (81-7)  | 693 (18-3)  | 1.36 (1.24, 1.50) | 1.33 (1.20, 1.48) |
| T3                             | 37 (43-5)    | 48 (56-5)   | 7.90 (5.13, 12.16) | 7.16 (4.58, 11.18) |
| Unknown                        | 7 (63-6)    | 4 (36-4)    | 3.48 (1.02, 11.89) | 2.58 (0.64, 10.37) |

| N category                     |             |             |    |                                  |                                    |
|--------------------------------|-------------|-------------|----|----------------------------------|                                    |
| N0                             | 10 865 (85-9) | 1784 (14-1) | 1.00 (reference) | 1.00 (reference) |
| N1                             | 3501 (83-0)  | 719 (17-0)  | 1.25 (1.14, 1.38) | 1.20 (1.09, 1.33) |
| N2                             | 521 (77-4)   | 152 (22-6)  | 1.78 (1.47, 2.14) | 1.51 (1.24, 1.84) |
| N3                             | 243 (77-6)   | 70 (22-4)   | 1.75 (1.34, 2.30) | 1.39 (1.05, 1.84) |
| Unknown                        | 295 (88-6)  | 38 (11-4)   | 0.79 (0.59, 1.01) | 0.75 (0.52, 1.09) |

Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.) and †values in parentheses are 95% per cent confidence intervals. BCS, breast-conserving surgery; HER2, human epidermal growth factor receptor 2. †Adjusted for type of surgery, year of operation, age, histological finding, differentiation grade, oestrogen receptor, HER2 status, T and N category. ‡Wald test.
In total, conversion to mastectomy was performed in 655 patients (3.6 per cent). The CMR was 3.7 and 3.2 per cent after BCS and OPS respectively ($P = 0.105$). Different CMRs were observed among the OPS techniques: 3.2 per cent for volume displacement, 2.9 per cent for volume reduction and 5.9 per cent for volume replacement. Over time, the unadjusted CMR decreased significantly from 4.3 to 2.7 per cent ($P = 0.003$) (Table S5, supporting information).

Multivariable analysis showed that patients who underwent OPS were less likely to undergo conversion to mastectomy than those who had BCS (OR 0.69, 0.58 to 0.84). Similar results were found for subgroups who had OPS with volume displacement (OR 0.71, 0.58 to 0.87) or volume reduction (OR 0.53, 0.33 to 0.84) (Table S5, supporting information). There was no difference in CMR between OPS with volume replacement and BCS (OR 1.07, 0.53 to 2.13). Conversion to mastectomy was more likely in patients with poor prognostic characteristics, including lobular histology ($P < 0.001$), larger tumour ($P < 0.001$) and more lymph node involvement ($P < 0.001$). In the matched cohorts (Tables S1–S4, supporting information), results of multivariable analyses were similar to those for the unmatched groups, in comparisons of OPS as a whole versus BCS (OR 0.70, 0.57 to 0.86), and OPS with volume displacement (OR 0.67, 0.54 to 0.84), volume reduction (OR 0.51, 0.30 to 0.89) or volume replacement (OR 1.13, 0.43 to 3.02) versus BCS.

**Discussion**

In this population-based cohort study, re-excision or conversion to mastectomy was less likely among patients who underwent OPS than BCS, although differences were modest. The re-excision rate and CMR were lower among patients who underwent OPS using volume displacement and reduction techniques, but both rates were similar after BCS and OPS with volume replacement, although numbers in the latter group were small. This large population-based study adjusted for confounders, and limited confounding by indication bias by means of propensity score matching.

Although no long-term differences in recurrence rates and survival between BCS and OPS have been reported\(^{11,19,22,43-45}\), current evidence regarding the impact of OPS on the re-excision rate is limited because the data are from single-centre studies with relatively few patients undergoing OPS (ranging from 31 to 1177), and in most studies the methodology was weak\(^{11,13,44,46-48}\). The present results are in line with a meta-analysis\(^8\) from 2018 that found a significantly lower risk of re-excision in patients who underwent OPS compared with those who had BCS (relative risk 0.66, 95 per cent c.i. 0.48 to 0.90). However, more recently, comparable re-excision rates after BCS and OPS were reported in two studies from Finland\(^{13}\) and Iceland\(^{11}\). In contrast to the present study, only relatively small numbers of patients were included, without extensive adjustment for confounders.

Since 2011, Danish guidelines\(^{31}\) have stated that OPS should be considered when, for example, tumour size and location do not allow a satisfactory cosmetic result with BCS. In the present study, use of OPS among patients who underwent BCS decreased between 2012 and 2018 (from 30.3 to 26.4 per cent), specifically in volume reduction and replacement techniques. A large multicentre study\(^{10}\) from the USA showed a significant rise in the OPS rate from 4.3 to 9.0 per cent between 2005 and 2016. Among those who underwent OPS, the percentage who had volume displacement was similar to that in the present study (85.2 and 83.4 per cent respectively). Nonetheless, the overall use of OPS here was still substantially higher than in most previous studies\(^{18,19}\).

Boost radiation is associated with serious side-effects such as fibrosis, radiation heart disease and second non-breast cancers\(^{49,50}\), and so re-excision may have been preferred over boost radiation, specifically in patients with a tumour bed in front of the heart\(^{51}\). Nonetheless, in the present study, the rate of secondary interventions among patients older than 50 years was similar in those undergoing BCS and OPS, although boost radiation was preferred to re-excision in the event of insufficient margins for those who underwent OPS. This was slightly surprising, as radiotherapy planning is challenging after OPS, because identification of the tumour bed can be difficult\(^{52}\). These findings highlight the challenge in balancing morbidity from re-excision with that of boost radiation, and the importance of close collaboration between surgeons and radiation oncologists. Any decision regarding re-excision or boost radiation should be made at a multidisciplinary team meeting.

Heterogeneous definitions of insufficient margins, ranging from ‘tumour within 10 mm from the ink margin’ to ‘tumour on ink’, may partly explain the difference between the findings here and those of other studies\(^{18,19}\). The present overall re-excision rate of 15.2 per cent is within the range (0–15.7 per cent) reported in other studies\(^{13,51-55}\) that used the same definition of ‘tumour on ink’. The associations between poor prognostic factors, such as larger tumour or lymph node involvement, and re-excision and conversion to mastectomy are in line with previous findings\(^{18,53,55}\). Future guidelines may highlight the additional risk when considering OPS in these patients.
The overall CMR of 3.6 per cent in this analysis is well below the mean of 6.2 per cent and within the range of 0–34.2 per cent reported in previous studies, and a systematic review of 55 studies. However, it is not in line with the results of a meta-analysis from 2014, which found a higher CMR for OPS with volume reduction and volume replacement compared with BCS. This may be explained partly by the fact that most included studies did not adjust for confounders and did not exclude patients diagnosed with in situ disease alone, because such patients are less likely to have a re-excision rate similar to that for invasive breast cancer.

The differing rates of re-excision between OPS techniques might be explained by the small absolute numbers, and consequently wide confidence intervals. Another explanation could be differences in patient or tumour factors used for surgical procedure selection. Breast and tumour size, tumour location and glandular density are, among other factors, used in selection of the preferred OPS technique, but also affect the likelihood of having a secondary mastectomy. For instance, patients with smaller breasts who require OPS with volume replacement may be less eligible for a secondary BCS, and may therefore undergo a secondary mastectomy when indicated.

The present data support the theory that OPS is associated with fewer re-excisions, although other explanations are possible. Patients and surgeons might be less willing to accept re-excisions following OPS because of the primary focus on the cosmetic result. Unfortunately, tumour margin data for the primary procedure are incomplete in the DBCG database for the early years of the present study and could therefore not be included.

Future studies should evaluate whether the effect of OPS on re-excision is similar in patients treated with and without neoadjuvant therapy, as patients who are considered candidates for neoadjuvant therapy, such as those with locally advanced tumours, are also candidates for OPS. Neoadjuvant chemotherapy can be used for tumour downstaging, making more patients eligible for BCS without OPS. It could therefore be argued that there might be less need for OPS in the future as use of neoadjuvant chemotherapy in most high-income countries has been increasing in recent years. Neoadjuvant chemotherapy has only been used for breast cancer downstaging in Denmark more recently, and patients receiving such treatment were not included in the present study. The increasing use of neoadjuvant chemotherapy might, however, explain the slight decrease in OPS in more recent years in this study.

That changing paradigm from primary BCS to more mastectomy seen in, for instance, the USA could also have influenced the present findings. Earlier reports from the DBCG database, however, showed that the proportion of patients undergoing primary mastectomy remained stable at around 25 per cent in Denmark during the inclusion period of the present study.

This study has several limitations. Several factors, such as breast size, smoking status and surgeons’ preference, are known to affect both the choice of surgery and outcomes. Likewise, local resources (such as operating times) and level of experience among staff members can affect both the use of OPS and re-excision rates. Unfortunately, information on these potential confounders was not available. Moreover, the rationale behind the choice of a specific surgical technique (such as rack mammoplasty or reduction with superior pedicle flap) is not registered by the DBCG. Residual confounding by indication could have been present as the matched analyses could only include available variables.

The present findings do not support the use of OPS in all patients undergoing BCS, but rather highlight the safety of OPS for those in whom a satisfactory cosmetic result could not be achieved with BCS alone. This study does not encourage the use of OPS in every patient, but emphasizes its appropriate use in selected patients who otherwise would not be eligible for breast conservation.

Acknowledgements

Study data can be made available upon reasonable request to the Scientific Committee of Surgery within the DBCG, and the Danish Clinical Registries. This study was supported by funding from the Stichting Professor Michaël-van Vloten Foundation, Nijibaker-Morra Foundation and the Leids University Foundation/Van Trigt Foundation.

Disclosure: The authors declare no conflict of interest.

References

1 Blichert-Toft M, Nielsen M, During M, Møller S, Rank F, Overgaard M et al. Long-term results of breast conserving surgery versus mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82T protocol. Acta Oncol 2008; 47: 672–681.
2 Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E et al. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012; 13: 412–419.
3 Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical
mammary gland surgery for early breast cancer. *N Engl J Med* 2002; 347: 1227–1232.

4 Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. *N Engl J Med* 1985; 312: 665–673.

5 Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. *N Engl J Med* 1981; 305: 6–11.

6 Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P; Danish Breast Cancer Cooperative Group. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. *Acta Oncol* 2016; 55(Suppl 2): 24–35.

7 Integraal Kankercentrum Nederland (IKNL). *Cijfers over kanker; overleving borstkanker* 2017; 2017. https://www.cijfersoverkanker.nl/selecties/overleving_borst/img5aehd4f1h4ee [accessed 1 December 2019].

8 van Bommel A, Sprock P, Mureau M, Siesling S, Smorenburg C, Tollenaar R et al. Breast-contour-preserving procedure as a multidisciplinary parameter of esthetic outcome in breast cancer treatment in The Netherlands. *Ann Surg Oncol* 2019; 26: 1704–1711.

9 Clough KB, Benyahi D, Nos C, Charles C, Sarfati I. Oncoplastic surgery: pushing the limits of breast-conserving surgery. *Breast* 2015; 21: 140–146.

10 Jonczyk MM, Jean J, Graham R, Chatterjee A. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. *Breast Cancer Res Treat* 2019; 173: 267–274.

11 Palsdottir EP, Lund SHL, Asgeirsson KSA. Oncoplastic breast-conserving surgery in Iceland: a population-based study. *Sund Sarg* 2018; 107: 224–229.

12 Morrow ES, Stallard S, Dougherty J, Malyon A, Barber M, Dixon JM et al. Oncoplastic breast conservation occupies a niche between standard breast conservation and mastectomy – a population-based prospective audit in Scotland. *Eur J Surg Oncol* 2019; 45: 1806–1811.

13 Niinikoski L, Leidemius MHK, Vaara P, Voynov A, Heikkilä P, Mattson J et al. Resection margins and local recurrences in breast cancer: comparison between conventional and oncoplastic breast conserving surgery. *Eur J Surg Oncol* 2019; 45: 976–982.

14 Isaacs AJ, Gemignani ML, Pusic A, Sedrakyan A. Association of breast conservation surgery for cancer with 90-day reoperation rates in New York state. *JAMA Surg* 2016; 151: 648–655.

15 Clough KB, van la Parra RDF, Thygesen IH, Levy E, Russ E, Halabi NM et al. Long-term results after oncoplastic surgery for breast cancer: a 10-year follow-up. *Ann Surg Oncol* 2018; 268: 165–171.

16 Clough KB, Kaufman GJ, Nos C, Bucimazza I, Sarfati IM. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. *Ann Surg Oncol* 2010; 17: 1375–1391.

17 Losken A, Dugal CS, Styblo TM, Carlson GW. A meta-analysis comparing breast conservation therapy alone to the oncoplastic technique. *Ann Plast Surg* 2014; 72: 145–149.

18 De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ et al. Outcomes after oncoplastic breast-conserving surgery in breast cancer patients: a systematic literature review. *Ann Surg Oncol* 2016; 23: 3247–3258.

19 Chen JY, Huang YJ, Zhang LL, Yang CQ, Wang K. Comparison of oncoplastic breast-conserving surgery and breast-conserving surgery alone: a meta-analysis. *J Breast Cancer* 2018; 21: 321–329.

20 Santos G, Urban C, Edelweiss MI, Zucca-Matthes G, de Oliveira VM, Arana GH et al. Long-term comparison of aesthetic outcomes after oncoplastic surgery and lumpectomy in breast cancer patients. *Ann Surg Oncol* 2015; 22: 2500–2508.

21 Kelsall JE, McCulley SJ, Brock L, Akerlund MTE, Macmillan RD. Comparing oncoplastic breast conserving surgery with mastectomy and immediate breast reconstruction: case-matched patient reported outcomes. *J Plast Reconstr Aesthet Surg* 2017; 70: 1377–1385.

22 Kelemen P, Pukanecik D, Ujhelyi M, Sávolt A, Kovács E, Ivády G et al. Comparison of clinicopathologic, cosmetic and quality of life outcomes in 700 oncoplastic and conventional breast-conserving surgery cases: a single-centre retrospective study. *Eur J Surg Oncol* 2019; 45: 118–124.

23 Bodilsen A, Bjerring E, Offersten BV, Vahl P, Ejlertsen B, Overgaard J et al. The influence of repeat surgery and residual disease on recurrence after breast-conserving surgery: a Danish Breast Cancer Cooperative Group Study. *Ann Surg Oncol* 2015; 22(Suppl 3): S476–S485.

24 Jeevan R, Jeevan A, Jeevan S, Jeevan T, Jeevan S. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of Hospital Episode Statistics. *BMJ* 2012; 345: e505.

25 Dutch Institute for Clinical Auditing (DICA). *Jaarrapportage 2017*. 2018. http://dica.nl/jaarrapportage-2017 [accessed 1 December 2019].

26 Waris ML, Wong JA, Rodriguez S, Wong JM, Jabo B, Wanis ML et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. *Br J Surg* 2019; 106: 384–394.

27 Dahlbäck C, Manjer J, Rehn M, Ringberg A. Determinants for patient satisfaction regarding aesthetic outcome and skin sensitivity after breast-conserving surgery. *World J Surg Oncol* 2016; 14: 303.
Impact of oncoplastic surgery on rates of re-excision and conversion to mastectomy 1771

29 Klit A, Tvedskov TF, Kroman N, Elberg JJ, Ejlertsen B, Henriksen TF. Oncoplastic breast surgery does not delay the onset of adjuvant chemotherapy: a population-based study. Acta Oncol 2017; 56: 719–723.

30 Jensen MB, Laenkoholm AV, Offersten BV, Christiansen P, Kroman N, Mouridsen HT et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. Acta Oncol 2018; 57: 13–18.

31 Danish Breast Cancer Cooperative Group (DBCG). DBCG retninglinjer 2011; 2012. http://dbcg.dk/PDF%20Filere/Erla%4_Kirurgisk_behandling_03.04.13.pdf [accessed 1 December 2019].

32 Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449–490.

33 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.

34 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–410.

35 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al.; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997–4013.

36 Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC Cancer Staging Handbook (7th edn), vol. XIX. Springer: New York, 2010.

37 Danish Breast Cancer Cooperative Group (DBCG). Retninglinjer Postoperativ strålebehandling 2016; 2016. http://dbcg.dk/PDF%20Filere/Kap_5%20Kirurgisk%20postoperativ%20strålebehandling_20%-%202016.pdf [accessed 1 December 2019].

38 Bodilsen A, Bjerre K, Offersten BV, Vahl P, Amby N, Dixon JM et al. Importance of margin width in breast-conserving treatment of early breast cancer. J Surg Oncol 2016; 113: 609–615.

39 Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399–424.

40 Groenwold RH. [Propensity scores in observational research.] Ned Tijdschr Geneeskd 2013; 157: A6179.

41 Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med 2011; 30: 1292–1301.

42 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083–3107.

43 Mansell J, Weiler-Mithoff F, Stallard S, Doughty JC, Mallon E, Romics L. Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast 2017; 32: 179–185.

44 Mazouni C, Naveau A, Kane A, Dunant A, Garbay JR, Leymarie N et al. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy. Breast 2013; 22: 1189–1193.

45 Borm KJ, Schönknecht C, Nestler A, Oechsner M, Waschulzik B, Combs SE et al. Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients. BMC Cancer 2019; 19: 907.

46 Chakravorty A, Shrestha AK, Sammugalingam N, Rapisarda F, Rocha N, Querci Della Rovere G et al. How safe is oncoplastic breast conservation? Comparative analysis with standard breast conserving surgery. Eur J Surg Oncol 2012; 38: 395–398.

47 Carter SA, Lyons GR, Kuerer HM, Bassett RL Jr, Oates S, Thompson A et al. Operative and oncologic outcomes in 9861 patients with operable breast cancer: single-institution analysis of breast conservation with oncoplastic reconstruction. Ann Surg Oncol 2016; 23: 3190–3198.

48 Mukhtar RA, Weng J, Piper M, Zyu Z, Fahrner-Scott K, Mamounas M et al. Breast conservation and negative margins in invasive lobular carcinoma: the impact of oncoplastic surgery and shave margins in 358 patients. Ann Surg Oncol 2018; 25: 3165–3170.

49 Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J et al.; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015; 16: 47–56.

50 Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762 468 patients. Radiother Oncol 2015; 114: 56–65.

51 Taylor CW, Nishet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s–1990s. Int J Radiat Oncol Biol Phys 2007; 69: 1484–1495.

52 Offersten BV, Boersma IJ, Kirkove C, Hol S, Aznar MC, Biete Sola A et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 2015; 114: 3–10.

53 Clough KB, Gouveia PF, Benyahi D, Maisonneuve P, Loschi P, Maisonneuve P et al. Oncological results of oncoplastic breast-conserving surgery: long term follow-up of a large series at a single institution: a matched-cohort analysis. Eur J Surg Oncol 2016; 42: 71–77.
55 Semprini G, Cattin F, Vaienti L, Brizzolari M, Cedolini C, Parodi PC. Oncoplastic surgery and cancer relapses: cosmetic and oncological results in 489 patients. *Breast* 2013; 22: 946–951.

56 Langhans L, Jensen MB, Talman MM, Vejborg I, Kroman N, Tvedskov TF. Reoperation rates in ductal carcinoma *in situ* vs invasive breast cancer after wire-guided breast-conserving surgery. *JAMA Surg* 2017; 152: 378–384.

57 Rezai M, Knispel S, Kellersmann S, Lax H, Kimmig R, Kern P. Systematization of oncoplastic surgery: selection of surgical techniques and patient-reported outcome in a cohort of 1035 patients. *Ann Surg Oncol* 2015; 22: 3730–3737.

58 Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E et al. Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer. *Ann Surg Oncol* 2015; 22: 3184–3190.

59 Danish Breast Cancer Cooperative Group (DBCG). *Kvalitetsindikatorrapport for Brystkreft 2017*. DBCG: Copenhagen, 2018.

60 Danish Breast Cancer Cooperative Group (DBCG). *Kvalitetsindikatorrapport for Brystkreft 2015*. DBCG: Copenhagen, 2016.

61 Lucas DJ, Sabino J, Shriver CD, Pawlik TM, Singh DP, Vertrees AE. Doing more: trends in breast cancer surgery, 2005 to 2011. *Am Surg* 2015; 81: 74–80.

62 Carstensen L, Rose M, Bentzon N, Kroman NT. Knowledge and opinions on oncoplastic surgery among breast and plastic surgeons. *Dan Med J* 2015; 62: A5030.

Supporting information

Additional supporting information can be found online in the Supporting Information section at the end of the article.